Arcus Biosciences Announces New Employment Inducement Grants
27 3월 2024 - 5:35AM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer, today
announced that the Compensation Committee of the Company’s Board of
Directors granted four new employees options to purchase a total of
18,400 shares of the Company’s common stock at an exercise price
per share of $16.47, which was the closing price on March 25, 2024,
and restricted stock units to acquire a total of 9,200 shares of
the Company’s common stock. The equity awards were granted pursuant
to the Company’s 2020 Inducement Plan, which was approved by the
Company’s Board of Directors in January 2020 pursuant to the
“inducement exception” under NYSE Listed Company Manual Rule
303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, the adenosine axis (CD73, dual
A2a/A2b receptor and CD39), AXL and HIF-2a. For more information
about Arcus Biosciences’ clinical and pre-clinical programs, please
visit www.arcusbio.com or follow us on X.
Inducement PR
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240326788469/en/
Investor Inquiries: Pia Eaves VP of Investor Relations
& Strategy (617) 459-2006 peaves@arcusbio.com
Media Inquiries: Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Arcus Biosciences (NYSE:RCUS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024